Prof. Amnon Peled is the founder and Chief Scientific Officer of Biokine Therapeutics Ltd. Prof. Peled is a world-renowned expert in chemokine research, specifically on the CXCR4 receptor. He has published over 80 peer-reviewed papers in prestigious journals, such as Blood, JCI and Science. Prof. Peled is currently a Professor at the Gene Therapy Institute, Hadassah Medical Center, Jerusalem where he directs a laboratory focusing on the role of chemokines and chemokine receptors for the treatment of cancer and immune diseases. Professor Peled’s work experience includes Millennium Pharmaceuticals Inc., where he was the head of a group studying CXCR4 function in allergy. Prof. Peled has a Ph.D. from the Department of Cell Biology at the Weizmann Institute of Science.
Dr. Eizenberg is an expert in the field of molecular biology and cancer research. She has a Ph.D. from the Department of Molecular Biology of the Cell at the Weizmann Institute of Science. She conducted post-doctoral studies in brain research and related disorders at the Department of Neurobiology, also at the Weizmann Institute of Science. Dr. Eizenberg is a co-founder of Biokine Therapeutics Ltd. and has been the Vice President of R&D of Biokine from its inception.
Michal Abraham Karni is Head of pre-clinical development at Biokine. Michal received her M.Sc in Medical Science at the Technion – Israel Institute of Technology in the field of Neuroimmunology. Her Ph.D thesis was in immunology at Harvard Medical School, in the Center for Neurologic Diseases, and focused on the immune regulation of autoimmunity. She continued her post-doctoral research at the Hebrew University in the laboratory of Prof. Amnon Peled, and focused on the role of chemokines and chemokine receptors in inflammation and cancer.